Publication | Closed Access
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
118
Citations
16
References
2008
Year
At doses evaluated, MGCD0103 appears tolerable and exhibits favorable PK and PD profiles with evidence of target inhibition in surrogate tissues.
| Year | Citations | |
|---|---|---|
Page 1
Page 1